

1 **MiRNA encoded PTEN's Impact on Clinical-Pathological Features and** 2 **Prognosis in Osteosarcoma: a Systematic Review and Meta-Analysis**

3
4 Edward Kurnia Setiawan Limijadi^{1¶}, Robin Novriansyah^{2,4¶}, Danendra Rakha Putra Respati^{3,4*},
5 Kevin Christian Tjandra^{3,4¶}

6
7 ¹Department of Clinical Pathology, Faculty of Medicine, Universitas Diponegoro, Semarang,
8 Indonesia

9 ²Department of Orthopaedic Surgery, Faculty of Medicine, Universitas Diopnegoro, Semarang,
10 Indonesia

11 ³Departement of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

12 ⁴Kariadi General Hospital, Semarang, Indonesia

13
14 ***Corresponding author:** Danendra Rakha Putra Respati; Department of Medicine, Faculty of
15 Medicine, Universitas Diponegoro; Jl. Prof. Sudarto, Tembalang, Kec. Tembalang, Kota
16 Semarang, Jawa Tengah 50275

17 Email: rakhapres@gmail.com

18 ¶ This author contributed equally to this work

19 **Abstract**

20 **Background:** Osteosarcoma (OSC) is considered one of the most common malignant bone tumours in
21 adolescents. Due to OSC's poor prognosis, a comprehensive approach to exploring these aspects is
22 highly needed to improve the survival probability of OSC. In this study, we tried to explore the
23 significance of miRNA-encoded PTEN for clinical-pathological features and prognostic value in
24 OSC. **Method:** We performed this systematic review and meta-analysis using articles and sources
25 published between 2013 and 2023 from six databases (Scopus, PubMed, ProQuest, Science Direct, Sage
26 Pub, and Cochrane). Included studies were clinical cross-sectional studies. Other study designs, articles

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 not written in English, without full text, and not relevant—were excluded. Then, ROBINS-I is used to
28 evaluate the distance. The results are constructed according to the PICOS criteria in a table. The
29 expression of miRNA related to OSC is assessed in the meta-analysis as the main outcome to determine
30 its ability as a diagnostic and prognostic agent for OSC. This systematic review followed the PRISMA
31 guidelines. **Results:** A total of 17 studies were included in the final screening. The meta-analysis
32 showed significantly increased ($p < 0.00001$) miRNA expression in patients with osteosarcoma
33 compared to healthy controlled with pooled md (2.85) (95% CI: 2.69, 3.02; $I^2 = 22\%$, $p = 0.20$), the high
34 inverse correlation ($p < 0.001$) between miRNA and PTEN expression was shown as mean effect size
35 (-0.681) (95% CI: -0.787, -0.536; $I^2 = 75\%$, $p < 0.00001$), and the prognostic evaluation of overall
36 survival was significantly increased in low expression miRNA ($p < 0.00001$) with pooled
37 OR. **Conclusion:** Fiveteen miRNAs from 17 studies were found, and together with PTEN expression,
38 they may serve as potential prognostic biomarkers for OSC. High-level levels of miRNA expression
39 are correlated with low PTEN expression, leading to a bad prognosis for OSC.

40 *Keywords: Osteosarcoma, miRNA-PTEN, Prognosis*

41 **1. Introduction**

42 Osteosarcoma (OSC) is the most frequent bone malignancy in both children and adults. It is a malignant
43 mesenchymal tumour that accounts for 20–40% of all occurrences of bone malignancies. The
44 metaphysis of the long bones in the lower extremities is the most frequent site of OSC, which is most
45 common in people between the ages of five and twenty-five [1]. The inferior extremities, particularly
46 the distal femur, proximal tibia, and proximal humerus, are shown to be the site of 74.5% of cases. In
47 the meantime, factors like as age, gender, tumour location, biomarker levels, onset, and metastatic
48 presence all affect the prognosis of OS. $61 \pm 15\%$ is the 5-year relative survival rate for all age groups,
49 varying based on disease onset and gender. However, this figure drastically decreases to $20 \pm 5\%$ in
50 patients with metastasis. Approximately 10-20% of OSC patients experience metastasis, with the lungs
51 being a common site of involvement [2].

52

53 The high fatality rate drives the need for a more comprehensive multidisciplinary approach to the
54 diagnosis and management of OSC. To date, several treatment options for OSC include surgical

55 excision, radiotherapy, and multi-agent systemic therapy. Several evaluations are required to ascertain
56 which therapy will yield the best response in the patients. Furthermore, invasive biopsy is still required
57 for OSC diagnosis evaluation and confirmation [3,4]. However, due to variations in sample collection,
58 the accuracy of the biopsy-derived diagnosis and prognosis can fluctuate. Therefore, the diagnostic
59 approach is an important aspect to develop to achieve better prognosis, and one method with great
60 potential is identifying biomarkers [5–7].

61

62 Biomarkers themselves can be used as therapeutic, prognostic, and diagnostic agents. MicroRNAs
63 (miRNAs) are a class of endogenous non-coding RNAs with lengths of 19-25 nt. They are involved in
64 differentiation, cell death, and the cell cycle by regulating gene expression through direct inhibition and
65 degradation of mRNA translation [8]. In malignancies, this inhibitory function makes them tumor
66 suppressors and biomarkers for the diagnosis and prognosis of patients. PTEN is one of the major tumor
67 suppressors that has been extensively studied for its effects on cancer development, such as breast
68 cancer, prostate cancer, and lung cancer. PTEN (phosphatase and tensin homolog deleted on
69 chromosome ten) is a candidate tumor suppressor located on chromosome 10q23. PTEN works in the
70 PI3K/AKT regulatory pathway, a lipid kinase family axis with the PIP3 product, which is involved in
71 controlling cell proliferation to prevent cell development into cancer. The increase and decrease in
72 PTEN expression are regulated by a number of proteins in posttranslational, posttranscriptional, and
73 transcriptional mechanisms. One of these proteins is miRNA, which suppresses PTEN expression
74 posttranscriptionally. In this systematic review and meta-analysis, we summarize current knowledge on
75 the correlation between miRNA-PTEN and its impact on the clinicopathological and prognostic aspects
76 of OSC, which has not been previously explored within the scope of a wide range of articles.

77 **2. Methods**

78 Eligibility criteria

79 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were used for
80 this systematic review [9]. From 2013 to 2023 (last search date September 20th, 2023), we have included
81 original content. The study included original research publications that met the inclusion criteria for
82 autologous clinical cross-sectional. Technical reports, editor's responses, narrative reviews, systematic

83 reviews, meta-analyses, non-comparative studies, in silico studies, in vitro studies, in vivo studies,
84 applied Scientific posters, research proposals, and conference abstracts were all diminished. Articles
85 not written in English, with incomplete content, and not related to the miRNA and PTEN Gene
86 expression in correlation to OSC as well as survival rate were also eliminated. The desired PICO criteria
87 of the selected products included i) patients with OSC; ii) miRNA and PTEN expression evaluation
88 towards OSC patients and its survival rate; iii) Comparison, normal cells either obtain from the same
89 patients or other normal patients; and iv) Results, miRNA and PTEN evaluation utilizing RT-qPCR and
90 two years survival rate.

91

92 Data search and selection

93 Research for this study were gathered through Scopus, PubMed, ProQuest, Science Direct, Sage Pub,
94 Cochrane database searches. We used the following combined keywords to capture all potentially
95 eligible literature in each databases: “(osteosarcoma) AND (miRNA OR microRNA) AND (PTEN)
96 AND (clinicopathology OR prognosis)”. The database was searched from its establishment until
97 September 20th 2023 during 10-year periods prior to this review. The boolean operator was utilized
98 among the Medical Subject Headings (MeSH) keywords determined from national institute of health
99 (NIH) national library of medicine browser. The studies were kept using Mendeley Group Reference
100 Manager in the authors' library. Clinical type articles were used as a filter in the Pubmed database, the
101 the research article type was used for the Scopus, PubMed, ProQuest, Science Direct, Sage Pub,
102 Cochrane database filter. All of these processes for article selection were conducted by the two
103 independent authors (DRPR, KCT) who performed the literature searching process. The identified
104 articles from those databases were first filtered according to their titles and abstracts, and then duplicates
105 were eliminated. The same two authors conducted a second round of full-text evaluations for these
106 publications that made it past the first screening round to determine whether they met our
107 inclusion/exclusion criteria. All differences were addressed by engaging in discussions with the other
108 author (EKSL, RN), who assessed the suitability of studies for inclusion in the synthesis.

109

110 Data extraction

111 After the final screening, the pertinent information from studies was retrieved and entered into a Google
112 Spreadsheet. Recorded data in characteristic table consisted of author, year, country, study design,
113 sample size, mean age, miRNA type, miRNA expression with poor prognosis (high or low), and cut-
114 off. All of the data extraction was done by two independent author (DRPR, KCT). The primary outcome
115 of this study consisting of the survival analysis, miRNA/PTEN correlation, and clinicopathology
116 features (TNM stage, metastasis, and gender). The desired outcome for the survival analysis was 5-year
117 Overall Survival (OS), defined as the time from the initiation of therapy until death from any cause.
118 Using hazard ratios (HR), the impact of miRNA expressions on survival was evaluated. If given by the
119 authors, a univariate HR estimate and 95% confidence intervals were taken straight from each study. If
120 not, the suggested approach was used to extract the p values of the log-rank tests, 95% confidence
121 intervals, the number of events, and the number of patients at risk in order to estimate the HR [10]. In
122 cases where the number of events and patients at risk was not reported, we use Engauge Digitizer
123 version 4.1 to reconstruct the kaplan-meier curves, then we calculated the HR using the same method
124 as before. In patients with aberrant miRNA, a pooled HR < 1 suggested a better prognosis, whereas a
125 pooled HR > 1 suggested a worse prognosis.

126

127 Study Risk of Bias Assessment (Qualitative Synthesis)

128 Risk-of-bias tool used to assess the bias of included studies was the ROBINS-I from Cochrane
129 Collaborations, was used by three independent author (KCT, DRPR, RN). Any disagreements
130 regarding the bias assessment were discussed further and settled between the 3 reviewers. The result is
131 shown in **Figure 2**. The authors' evaluations were categorized as "low risk," "high risk," or "some
132 concerns" of bias. For analyzing the quality of included studies, we used Newcastle-Ottawa Scale
133 (NOS) from the Ottawa Hospital Research Institute (OHRI), a quality appraisal tool for cohort and
134 cross-sectional studies which includes 3 domains of assessment: (1) selection of participants; (2)
135 comparability between exposed and non-exposed cohort; and (3) outcome ascertainment [11]. For
136 cross-sectional research, the maximum possible score ranges from 0 to 10, while for cohort studies, it

137 ranges from 0 to 9. Articles with a score of at least 7 were deemed to have "good" quality. To maintain
138 the validity of the data included in the current investigation, papers that were judged to have a high risk
139 of bias will be eliminated from the systematic review.

140

141 Statistical Analysis

142 The results were displayed in the characteristic table as, mean difference (MD) with standard deviation
143 (SD) for miRNA expression with poor prognosis, HR with a 95% confidence interval (CI) for OS, and
144 correlation coefficient (r) with a 95%CI for miRNA/PTEN expression. Gender, TNM stage, and
145 metastatic status were presented as odd ratios (OR) with 95% CI. For pooled analysis, we converted the
146 data expressed as median and interquartile range (IQR) or as median, minimum, and maximum into
147 mean and standard deviations (SD) using a combination formula from Luo D et al. and Wan X et al
148 [12,13]. The I-squared (I²) statistic was employed in this review to evaluate the heterogeneity amongst
149 studies, with I² values greater than 50% classified as significant heterogeneity. When the included
150 studies were deemed homogeneous (little variability in study results or variation owing to random
151 error), as shown by an $P \geq 0.10$ or $I^2 \leq 50\%$, meta-analysis was performed using a fixed-effect model
152 (FEM). Otherwise, we used a random-effect model (REM) if $P < 0.10$ or $I^2 > 50\%$. The pooled mean
153 difference estimate was presented in a forest plot. When there were more than 10 studies on each
154 outcome of interest, a publication bias analysis was conducted using the funnel plot and Egger's test; if
155 an asymmetry in the funnel plot was discovered, we planned to review the characteristics to determine
156 whether the observed asymmetry could be attributed to publication bias or alternative factors such as
157 methodological heterogeneity among the studies. All of the analyses were carried out using
158 Comprehensive Meta-Analysis software, which can be accessed at <https://meta-analysis.com/>.

159

160 **3. Result**

161 Study Selection

162 A total of 12,939 studies were found in the database (5622 from Scopus, 31 from Pubmed, 5311 from
163 Proquest, 1720 from Science Direct, 116 from Sage Pub, and 156 from Cochrane). Then, 4842 studies

164 were imported to the Mendeley Group Reference Manager in the authors' library after the
165 aforementioned criteria were added, and this was done before the selection procedure. The number of
166 4312 studies was eliminated from this process due to irrelevant topics. Eventually, 561 studies were
167 screened manually by the authors. Out of all, 530 studies, they did not provide sufficient data to answer
168 the research question, and because their study designs did not meet the criteria for inclusion (clinical
169 cross-sectional), two studies were removed due to duplication, and three were removed due to
170 irretrievable full text. The retrieval of the complete text for the remaining twenty-six studies was then
171 tested. After the full text reading was done, only seventeen articles were considered eligible to be
172 obtained as a result. The flow chart for the PRISMA diagram illustrating our research selection
173 procedure is shown in **Figure 1**. Using the Cochrane ROBINS-I tool, the seventeen included studies
174 were evaluated for eligibility. All seventeen of the listed studies from this process passed the evaluation
175 bias check. The PRISMA flow chart contained records of the research selection procedures.

176

177 **Figure 1.** PRISMA 2020 flow diagram.

178

179 Study Characteristics

180 The seventeen studies that made up this systematic review comprised a total of 760 participants. These
181 each four studies were conducted in different countries. Studies were carried out in Japan, South Korea,
182 France, China, USA, Iran, Singapore, and Spain. The complete study characteristics, including the
183 PICO of each study, are stated in **Table 1**.

184

185 **Table 1.** Study Characteristic

186

187

	No	Author	miR type	Sample type	Sample size		Cut off	MiRNA expression	Assay method
					miRNA high	miRNA low			
188	1	Zhao D., et.al.;2017	miRNA-19a	Tissue	25	25	NR	upregulated	RTq-PCR
189	2	Chen J., et.al.;2015	miRNA-130a	Tissue	86	86	median	upregulated	RTq-PCR
190	3	Yuan H., et.al.;2015	miRNA-1908	Tissue	46	9	NR	upregulated	RTq-PCR
191	4	Hu X., et.al.;2018	miRNA-21	Tissue	46	20	NR	upregulated	RTq-PCR
192	5	Liu Q., et.al.;2018	miRNA-29	Tissue	60	60	median	upregulated	RTq-PCR
193	6	Liu J., et.al.;2015	miRNA-214	Tissue	22	22	NR	upregulated	RTq-PCR
194	7	Gao Y., et.al.;2014	miRNA-17	Tissue	28	28	NR	upregulated	RTq-PCR
195	8	Zhuang M., et.al.;2018	miRNA-524	Tissue	20	20	NR	upregulated	RTq-PCR
196	9	Sun C.,et.al.;2022	miRNA-181a-5p	Tissue	N/A	N/A	NR	upregulated	RTq-PCR
197	10	Zhang H.,et.al.;2016	miRNA-148a	Tissue	92	92	median	upregulated	RTq-PCR
198	11	Zhu J.,et.al.;2015	miRNA-221	Tissue	16	12	NR	upregulated	RTq-PCR
199	12	Yu W.,et.al.;2020	miRNA-744	Tissue	25	25	NR	upregulated	RTq-PCR
200	13	Fu Y.,et.al.;2020	miRNA-208a-3p	Tissue	10	10	NR	upregulated	RTq-PCR
201	14	Xiao J.,et.al.;2017	miRNA-92a	Tissue	68	68	median	upregulated	RTq-PCR
202	15	Yu L.,et.al.;2017	miRNA-214	Tissue	15	15	NR	upregulated	RTq-PCR
203	16	Tian Z.,et.al.;2014	miRNA-128	Tissue	100	100	median	upregulated	RTq-PCR
204	17	Zhao H., et.al.;2019	miRNA-21 miRNA-221	Tissue	NR NR	NR NR	median	upregulated	RTq-PCR

205 *Risk of Bias in Studies*

206 Each cohort and cross-sectional study underwent a thorough assessment of its quality using the
 207 ROBINS-I risk-of-bias method. In nine of the investigations, there were four studies identified as a
 208 study with some concern of bias due to unclear randomization process between the allocation of
 209 intervention and control groups. An overview of the bias risk assessment is shown in **Figure 2**.

210

211 **Figure 2.** Risk of Bias Assessment

212

213

214 *Clinicopathologies*

215 A meta-analysis of five studies was used to evaluate the gender clinicopathologic relationship between
216 OSC overexpression and miRNA encoding PTEN. A non-significant effect ($P = 0.28$) with a pooled
217 odds ratio (OR) of (1.24) (95% CI: 0.84, 1.83) is seen in **Figure 3** forest plot. This outcome suggests
218 that events do not differ for males and females. Additionally, the forest plot demonstrated heterogeneity
219 for the gender odds ratio clinicopathology ($I^2 = 0\%$; $P = 0.53$). **Figure 4** displays an analysis of the
220 metastatic clinicopathologic associated with miRNA encoding PTEN for OSC from three journals. A
221 significant effect ($P < 0.00001$) was seen in the forest plot, with a pooled OR of 0.24 (95% CI: 0.13,
222 0.43). The combined OR showed that an increase in the events leading to OSC metastasis was caused
223 by over-expression of the miRNA encoding PTEN. The results showed heterogeneity ($I^2 = 12\%$; $P =$
224 0.32). The assessment of OSC development entailed a review of its TNM staging concerning miRNA
225 encoding PTEN, as shown in **Figure 5**. A significant effect ($P = 0.02$) can be seen in the forest plot,
226 where the pooled odds ratio (OR) was 0.59 (95% CI: 0.38, 0.93). The cumulative OR indicated that an
227 unfavourable prognosis for OSC was linked to over-expression of miRNA encoding PTEN.
228 Heterogeneity was notably found ($I^2 = 11\%$; $P = 0.35$).

229

230 **Figure 3.** Forest plot of gender-related to miRNA overexpression

231

232 **Figure 4.** Forest plot of metastasis-related to miRNA overexpression

233

234 **Figure 5.** Forest plot of TNM staging related to miRNA encoding PTEN overexpression

235

236 *Prognostic survival analysis*

237 The correlation between OS rate and miRNA overexpression was thoroughly examined in this study.
238 The assessment, depicted in **Figure 6** through meta-analysis, revealed a substantial effect ($P < 0.00001$),
239 with a pooled Hazard Ratio (HR) of -12.38 (95% CI: -13.75, -11.01). The aggregated HR underscored

240 that OSC patients exhibiting miRNA encoding PTEN overexpression face a mortality risk more than
241 twice as high. Noteworthy heterogeneity was observed ($I^2 = 20\%$; $P = 0.27$).

242

243 **Figure 6.** Forest plot of overall survival related to miRNA encoding PTEN overexpression

244

245 *miRNA and PTEN correlation for osteosarcoma expression*

246 A meta-analysis comparing the population with OSC to the healthy population was conducted as part
247 of the inquiry into miRNA overexpression. A significant effect ($P < 0.00001$) was seen in the forest
248 plot, as shown in **Figure 7**, with a pooled mean difference (MD) of 2.83 (95% CI: 2.65, 3.02). When
249 comparing the expression of miRNA in patients with OSC to that in healthy individuals, the combined
250 MD showed a substantial increase in expression. Heterogeneity was found, notably ($I^2 = 27\%$; $P = 0.16$).
251 Meanwhile, this meta-analysis examined PTEN expression and its relationship to miRNA expression.
252 This result was shown in **Figure 8**. A significant effect ($P < 0.00001$) was seen in the forest, with a
253 pooled mean difference (MD) of -1.51 (95% CI: -1.68, -1.34). PTEN expression was lower in patients
254 with miRNA overexpression, according to the pooled MD. Heterogeneity was found ($I^2 = 77\%$; $P <$
255 0.00001).

256

257 **Figure 7.** Forrest plot of high/low miRNA expression

258

259 **Figure 8.** Forrest plot of miRNA and PTEN expression correlation

260

261 *Reporting biases*

262 Egger's test and Begg's funnel plot were used to assess the meta-analysis's publication bias. The funnel
263 plot among the 13 research did not clearly demonstrate any signs of asymmetry, as **Figure 9** illustrates.
264 Furthermore, Egger's test in the meta-analysis indicated no evidence of publication bias ($P > 0.05$).

265

266 **Figure 9.** Funnel plot of high/low miRNA expression

267

268 4. Discussion

269 The identification of Phosphatase and tensin homolog deleted on chromosome ten (PTEN) dates back
270 to 1997. It marked the inaugural recognition of a tumor suppressor gene possessing tyrosine
271 phosphatase activity. The nomenclature "phosphatase and tensin homolog deleted on chromosome ten"
272 was derived from its location at 10q23 [14]. Crucial to the principal regulatory pathway of cell growth
273 is phosphatidylinositol 3,4,5-trisphosphate (PIP3), capable of stimulating cell growth and initiating
274 tissue cell apoptosis [15]. PTEN intervenes by dephosphorylating one of the three phospho-groups of
275 PIP3, modulating the cell growth pathway and prompting cellular self-destruction, thereby instigating
276 abnormal cell death[16]. Furthermore, PTEN's tumor suppressor role extends to cell cycle regulation,
277 where it fosters p27Kip1 binding to the CyclinE/cyclin-dependent kinase 2 (CDK2) complex, inhibiting
278 CDK2 kinase activity. This inhibition prevents cells from entering the S phase and correlates with the
279 down-regulation of RB protein phosphorylation levels [17].

280
281 PTEN down-regulation has been documented in various malignant tissues such as glioma, endometrial
282 cancer, lung cancer, and prostate cancer [8,18,19]. Previous investigations into the impact of PTEN
283 expression on OSC patient prognosis yielded conflicting results. For instance, Sun et al. [16] posited
284 that positive PTEN expression is unrelated to gender, age, tumor size, and metastasis, while Han et al.
285 and Xie et al [20–22]. reported an association between PTEN expression and OSC metastasis. In this
286 comprehensive report, a meta-analysis encompassing all available studies on PTEN expression and
287 OSC patients was conducted to elucidate its relationship with the prognosis of OSC.

288
289 This study demonstrates that PTEN is a direct target of multiple miRNAs, including miRNA-19a,
290 miRNA-130a, miRNA-1908, miRNA-21, miRNA-29, miRNA-17, miRNA-524, miRNA-181a-5p,
291 miRNA-148a, miRNA-221, miRNA-744, miRNA-208a-3p, miRNA-92a, miRNA-214, and miRNA-
292 128, which are overexpressed in OSC tissues compared to normal tissues. PTEN shows a negative
293 correlation with miRNA expression in OSC tissue. Studies by Gao Y. (2014) demonstrated PTEN as a
294 target of miRNA-17, suppressing the WT 3'-UTR in HEK293 cells [23]. Yuan H (2015) reported that
295 miR-1908 overexpression reduces PTEN expression, confirmed through luciferase activity comparison

296 in OSC cells transfected with miRNA-1908 [24]. Xiao J. (2017) reported increased miR-92a expression
297 reduces PTEN levels, leading to increased expression of p-AKT(Ser473), mTOR, p-p27(Thr157), and
298 p-MDM2(Ser166) in MG-63 cells, indicating miR-92a regulates the PTEN/AKT pathway in OSC cells
299 [25].

300

301 Previous studies have detailed the post-transcriptional regulation of oncogenes and tumor suppressors
302 by microRNAs (miRNAs), involving epigenetic mechanisms such as DNA methylation, chromatin
303 modification, and non-coding RNAs (ncRNAs), including miRNAs and long non-coding RNAs
304 (lncRNAs). MiRNAs targeting PTEN primarily focus on the slender region of the 3' untranslated region
305 (3'UTR), leading to the downregulation of PTEN expression [8,19]. Consequently, the overexpression
306 of miRNAs suppresses PTEN function in the PI3K/Akt pathway, promoting OSC growth [26,27]. In
307 tumor cells, PTEN acts as an anti-proliferative agent by inhibiting cyclin D1 transcription through AKT
308 inactivation and increasing lipid phosphatase activity in the cytoplasm, resulting in elevated p27
309 expression. PTEN also mediates apoptosis through the activation of caspase-3 and TP53 [28].
310 Furthermore, PTEN regulates the Epithelial Mesenchymal Transition (EMT), an early stage in the
311 metastasis cascade [29,30]. Thus, PTEN indirectly influences the prognosis of OSC and other tumors,
312 such as breast, kidney, and lung cancers [31–33].

313

314 We further analyzed the correlation between the expression of these miRNAs and the prognosis and
315 clinicopathological features of OSC. A comprehensive systematic review and meta-analysis clarified
316 the prognostic value of miRNAs and PTEN in OSC. An increase in miRNAs targeting PTEN in OSC
317 tissues closely correlates with worse OS Xiao J. (2017) reported that OS tissues with overexpression of
318 miRNA-92a have worse overall and event-free survival (EFS) [25]. Detailed confirmation of the role
319 of miRNAs in OSC prognosis was provided by Zhao H. (2019), comparing miRNA-128-high/PTEN-
320 low, miRNA-128-low/PTEN-high, and miR-128-low/PTEN-low groups, showing that upregulation of
321 miRNA-128 and downregulation of PTEN constitute the group with the worst prognosis and
322 clinicopathological features [34]. Zhang H. (2016) explained their findings regarding the correlation

323 between overexpression of miRNA-148a in OSC tissues and worse OS and clinicopathological features
324 [35].

325

326 It is essential to note that OSC prognosis can be influenced by various risk factors beyond miRNA
327 expression, with patient clinicopathological features also playing a role. Therefore, we evaluated the
328 relationship between miRNA expression and OSC clinicopathological features. The relevance of each
329 clinicopathological feature and the overexpression of miRNAs to OSC prognosis was explained in a
330 study by Zhao H. (2019) [34]. MiRNA-21, miRNA-221, metastasis, and tumor staging were identified
331 as major independent risk factors impacting OSC prognosis compared to other parameters. It was also
332 indicated that the overexpression of miRNA-21 and miRNA-221 has a more significant impact on worse
333 prognosis than metastasis and tumor staging. To further confirm these findings, we investigated the
334 correlation of miRNAs with gender, metastasis, and OSC staging.

335

336 We found that positive miRNA expression significantly associated with female gender, metastasis,
337 TNM staging, and poor prognosis. Chen J. (2015) suggested that overexpression of miRNA-130a
338 promotes OSC metastasis and EMT through PTEN inhibition, confirmed by transwell assay results
339 showing increased migration and invasion in HOS58 cells [36]. Hu X. (2018) and Zhu J. (2015)
340 indicated that positive expression of miRNA-21 and miRNA-221 increases proliferation, invasion, and
341 migration through PTEN downregulation, subsequently promoting metastasis [37,38].

342

343 The study exhibits several strengths, including a comprehensive approach through systematic review
344 and meta-analysis, involving 17 studies published between 2013 and 2023 from diverse databases.
345 Methodological rigor is maintained with the use of the ROBINS-I tool for risk assessment, and
346 adherence to PRISMA guidelines ensures transparency. Clinically relevant outcomes are explored,
347 shedding light on the significance of miRNAs encoded PTEN in OSC. However, limitations include a
348 restriction to clinical cross-sectional studies, potentially limiting the diversity of evidence. Exclusion of
349 non-English articles introduces language bias, and the temporal limitation to 2013-2023 might overlook
350 newer developments. Heterogeneity in meta-analysis and the focus on a limited set of outcome

351 measures may impact the generalizability and comprehensiveness of the findings. Overall, the study
352 suggests 15 miRNAs, in conjunction with PTEN expression, as potential prognostic biomarkers for
353 OSC, though the findings should be interpreted considering these limitations.

354

355 However, this study has several unavoidable limitations. First, the analysis is based on a set of
356 publications. Second, some Hazard Ratios (HR) and 95% Confidence Intervals (CI) were obtained
357 through survival curve extraction, potentially reducing study accuracy. Third, the majority of studies
358 were conducted in the Asian region, which may affect the generalizability of the results. Fourth, some
359 included studies had small sample sizes, potentially increasing sample bias and randomization errors.

360

361 **5. Conclusion**

362 Using a meta-analysis technique, we examined the clinicalpathology characteristics and prognostic
363 usefulness of miRNA-encoded PTEN in patients with OSC in this study. In conclusion, the
364 overexpression of miRNAs encoded PTEN contributes to the unfavourable clinicopathological features
365 and the prognosis of OSC. These factors are primarily associated with female gender, metastasis, and
366 advanced TNM staging. Furthermore, miRNA expression has a greater impact on the decreased OS in
367 OSC.

368

369 **STATEMENTS AND DECLARATIONS**

370 **Registration**

371 On August 8, 2023, this systematic review and meta-analysis was registered to the Open Science
372 Framework (OSF). The registration was identified as MiRNA encoded PTEN's Impact on Clinical-
373 Pathological Features and Prognosis in Osteosarcoma: a Systematic Review and Meta-Analysis.
374 <https://doi.org/10.17605/OSF.IO/647WF>.

375

376 **Availability of data and materials:**

377 *Underlying data*

378 All data underlying the results are available as part of the article and no additional source data are
379 required.

380 *Reporting guidelines*

381 **Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#)**
382 **(CC-BY 4.0).**

383 **Competing Interest: All authors declare that they have no competing interests**

384 **Funding: None**

385 **Acknowledgment: None**

386 **Ethical Approval: Not applicable**

387 **Patient's Consent for Publication: Not applicable**

388

389 **REFERENCES**

- 390 1. Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global
391 assessment. *Cancer Causes & Control*. 2015 Aug 9;26(8):1127–39.
- 392 2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to
393 2004. *Cancer*. 2009 Apr 1;115(7):1531–43.
- 394 3. Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, et al. Prognostic
395 Significance of Serum Lactate Dehydrogenase in Osteosarcoma of the Extremity: Experience
396 at Rizzoli on 1421 Patients Treated over the Last 30 Years. *Tumori Journal*. 2004 Sep
397 17;90(5):478–84.
- 398 4. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – Where do we stand? A
399 state of the art review. *Cancer Treat Rev*. 2014 May;40(4):523–32.
- 400 5. Wadhwa N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors.

- 401 Indian J Orthop. 2014 May;48(3):247–54.
- 402 6. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary
403 Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant
404 Cooperative Osteosarcoma Study Group Protocols. *Journal of Clinical Oncology*. 2003 May
405 15;21(10):2011–8.
- 406 7. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic
407 Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702
408 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. *Journal of*
409 *Clinical Oncology*. 2002 Feb 1;20(3):776–90.
- 410 8. Kobayashi E, Hornicek FJ, Duan Z. MicroRNA Involvement in Osteosarcoma. *Sarcoma*.
411 2012;2012:359739.
- 412 9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T C, Mulrow CD et al. The
413 PRISMA 2020 statement: an updated guideline for reporting systematic
414 reviews *BMJ* 2021; 372 :n71 doi:10.1136/bmj.n71
- 415 10. Guyot, P., Ades, A., Ouwens, M.J. *et al.* Enhanced secondary analysis of survival data:
416 reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res*
417 *Methodol* **12**, 9 (2012). <https://doi.org/10.1186/1471-2288-12-9>
- 418 11. GA WellsBS, O’Connell D, Peterson J, et al. The Newcastle- Ottawa scale (NOS) for
419 assessing the quality of nonrandomised studies in meta- analyses. 2013.
- 420 12. Wan, X., Wang, W., Liu, J. *et al.* Estimating the sample mean and standard deviation from the
421 sample size, median, range and/or interquartile range. *BMC Med Res Methodol* **14**, 135 (2014).
422 <https://doi.org/10.1186/1471-2288-14-135>. doi.org/10.1186/1471-2288-14-135
- 423 13. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size,
424 median, mid-range, and/or mid-quartile range. *Statistical Methods in Medical Research*.
425 2018;27(6):1785-1805. doi:[10.1177/0962280216669183](https://doi.org/10.1177/0962280216669183)
- 426 14. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and
427 prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1
428 (European and American Osteosarcoma Study) cohort. *Eur J Cancer*. 2019 Mar;109:36–50.

- 429 15. Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: a review of current and future
430 therapeutic approaches. *Biomed Eng Online*. 2021 Mar 2;20(1):24.
- 431 16. Zamborsky R, Kokavec M, Harsanyi S, Danisovic L. Identification of Prognostic and
432 Predictive Osteosarcoma Biomarkers. *Med Sci (Basel)*. 2019 Feb 11;7(2).
- 433 17. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr. The
434 role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell
435 cycle arrest and tumor growth inhibition. *J Biol Chem*. 2003 Jun 27;278(26):23441-50. doi:
436 10.1074/jbc.M300848200.
- 437 18. Dong Z, Liao Z, He Y, Wu C, Meng Z, Qin B, et al. Advances in the Biological Functions and
438 Mechanisms of miRNAs in the Development of Osteosarcoma. *Technol Cancer Res Treat*.
439 2022;21:15330338221117386.
- 440 19. Llobat L, Gourbault O. Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.
441 *Biomedicines*. 2021 Apr 23;9(5).
- 442 20. Sun C, Chen C, Chen Z, Guo J, Yu ZH, Qian W, et al. MicroRNA-181a-5p Promotes
443 Osteosarcoma Progression via PTEN/AKT Pathway. *Analytical Cellular Pathology*. 2022 Mar
444 8;2022:1–13.
- 445 21. Xie L., Liao Y., Shen L., Hu F., Yu S., Zhou Y., Zhang Y., Yang Y., Li D., Ren M., et al.
446 Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on
447 RNA-seq. *Oncotarget*. 2017;8:42525–42536. doi: 10.18632/oncotarget.17208.
- 448 22. Han G, Wang Y, Bi W, Jia J, Wang W. MicroRNA-124 functions as a tumor suppressor and
449 indicates prognosis in human osteosarcoma. *Exp Ther Med*. 2015;9:679–684.
- 450 23. Gao Y, Luo L hui, Li S, Yang C. miR-17 inhibitor suppressed osteosarcoma tumor growth and
451 metastasis via increasing PTEN expression. *Biochem Biophys Res Commun*. 2014
452 Feb;444(2):230–4.
- 453 24. Yuan H, Gao Y. MicroRNA-1908 is upregulated in human osteosarcoma and regulates cell
454 proliferation and migration by repressing PTEN expression. *Oncol Rep*. 2015
455 Nov;34(5):2706–14.
- 456 25. Xiao J, Yu W, Hu K, Li M, Chen J, Li Z. miR-92a promotes tumor growth of osteosarcoma by

- 457 targeting PTEN/AKT signaling pathway. *Oncol Rep.* 2017 Mar;37(4):2513–21.
- 458 26. Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. *Genes*
459 *Cancer.* 2010 Dec;1(12):1170–7.
- 460 27. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene.*
461 2008 Sep 18;27(41):5497–510.
- 462 28. He L. Posttranscriptional Regulation of PTEN Dosage by Noncoding RNAs. *Sci Signal.* 2010
463 Nov 2;3(146).
- 464 29. Qi Y, Liu J, Chao J, Scheuerman MP, Rahimi SA, Lee LY, et al. PTEN suppresses epithelial–
465 mesenchymal transition and cancer stem cell activity by downregulating Abi1. *Sci Rep.* 2020
466 Jul 29;10(1):12685.
- 467 30. Fedorova O, Parfenyev S, Daks A, Shuvalov O, Barlev NA. The Role of PTEN in Epithelial–
468 Mesenchymal Transition. *Cancers (Basel).* 2022 Aug 3;14(15):3786.
- 469 31. Baig RM, Mahjabeen I, Sabir M, Masood N, Hafeez S, Malik FA, et al. Genetic changes in the
470 PTEN gene and their association with breast cancer in Pakistan. *Asian Pac J Cancer Prev.*
471 2011;12(10):2773–8.
- 472 32. Liu L, Huang L, He J, Cai S, Weng Y, Huang S, et al. PTEN inhibits non-small cell lung
473 cancer cell growth by promoting G0/G1 arrest and cell apoptosis. *Oncol Lett.* 2018 Nov 16
- 474 33. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, et al. Molecular Signatures
475 of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after
476 Nephrectomy. *Cancer Epidemiology, Biomarkers & Prevention.* 2009 Mar 1;18(3):894–900.
- 477 34. Zhao H, Yan P, Wang J, Zhang Y, Zhang M, Wang Z, et al. Clinical significance of tumor
478 miR-21, miR-221, miR-143, and miR-106a as biomarkers in patients with osteosarcoma. *Int J*
479 *Biol Markers.* 2019 Jun 14;34(2):184–93.
- 480 35. Zhang H, Wang Y, Xu T, Li C, Wu J, He Q, et al. Increased expression of microRNA-148a in
481 osteosarcoma promotes cancer cell growth by targeting PTEN. *Oncol Lett.* 2016
482 Nov;12(5):3208–14.
- 483 36. Chen J, Yan D, Wu W, Zhu J, Ye W, Shu Q. MicroRNA-130a promotes the metastasis and
484 epithelial-mesenchymal transition of osteosarcoma by targeting PTEN. *Oncol Rep.* 2016


- 485 Jun;35(6):3285–92.
- 486 37. Hu X, Li L, Lu Y, Yu X, Chen H, Yin Q, et al. miRNA-21 inhibition inhibits osteosarcoma
487 cell proliferation by targeting PTEN and regulating the TGF- β 1 signaling pathway. *Oncol Lett.*
488 2018 Jul 19
- 489 38. Zhu J, Liu F, Wu Q, Liu X. miR-221 increases osteosarcoma cell proliferation, invasion and
490 migration partly through the downregulation of PTEN. *Int J Mol Med.* 2015 Nov;36(5):1377–
491 83.
- 492

Study	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall Bias
Zhao D., et.al.,2017	Low	Low	Low	Low	Low	Low	Low	Low
Chen J., et.al.,2015	Low	Low	Low	Low	Low	Low	Low	Low
Yuan H., et.al.,2015	Low	Low	Low	Low	Low	Low	Low	Low
Mu X., et.al.,2018	Low	Low	Low	Low	Low	Low	Low	Low
Li Q., et.al.,2018	Low	Low	Low	Low	Low	Low	Low	Low
Li J., et.al.,2015	Low	Low	Low	Low	Low	Low	Low	Low
Gao Y., et.al.,2014	Low	Low	Low	Low	Low	Low	Low	Low
Zhuang M., et.al.,2018	Moderate	Low	Low	Moderate	Low	Low	Low	Moderate
Sun C.,et.al.,2022	Moderate	Low	Low	Moderate	Low	Low	Low	Moderate
Zhang H.,et.al.,2016	Low	Low	Low	Low	Low	Low	Low	Low
Zhu J.,et.al.,2015	Low	Low	Low	Low	Low	Low	Low	Low
Yu W.,et.al.,2020	Low	Low	Low	Low	Low	Low	Low	Low
Fu Y.,et.al.,2020	Low	Moderate	Low	Moderate	Low	Low	Low	Moderate
Xiao J.,et.al.,2017	Low	Low	Low	Low	Low	Low	Low	Low
Yu L.,et.al.,2017	Low	Low	Low	Low	Low	Low	Low	Low
Tian Z.,et.al.,2014	Low	Low	Low	Low	Low	Low	Low	Low
Zhao, et.al.,2019	Low	Moderate	Low	Low	Low	Low	Low	Moderate

medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .


Figure 2. Risk of Bias Assessment

2.3 Gender




medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

2.1 Metastasis



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


2.2 TNM Stage



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 5. Forest plot of TNM staging related to miRNA en


2.4 Overall survival



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 6. Forest plot of overall survival related to miRNA


1.1 miRNA expression



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 7. Forrest plot of high/low miRNA expression

1.2 miRNA/PTEN Correlation



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.16.24307477>; this version posted May 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 8. Forrest plot of miRNA and PTEN expression correlation




Figure 9. Funnel plot of high/low miRNA expression




Figure 1. PRISMA 2020 flow diagram.